ArticleThe Journal of infectious diseases2016
An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Infection Rates and Risk Factors for Infection Among Health Workers During Ebola and Marburg Virus Outbreaks: A Systematic Review.The Journal of infectious diseases · 2018Pooled it
- Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.The Journal of general virology · 2025Article
- Ebola Virus Disease Sensitization: Community-Driven Efforts in Sierra Leone.Journal of community health · 2024Article
- 50 Years of Lassa Fever Research.Current topics in microbiology and immunology · 2023Article
- The evidence remains clear: SARS-CoV-2 emerged via the wildlife trade.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans.Viruses · 2021Article
- Factors associated with length of stay and treatment outcome of Ebola patients treated at an Ebola treatment center in Sierra Leone during the peak period of the West African Ebola outbreak 2013-2016.Archives of public health = Archives belges de sante publique · 2021Article
- Health seeking behavior after the 2013-16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone.PLoS neglected tropical diseases · 2021Article
- Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012-2019.Microorganisms · 2021Article
- The CRISPR revolution and its potential impact on global health security.Pathogens and global health · 2021Review
- Multivalent DNA Vaccines as A Strategy to Combat Multiple Concurrent Epidemics: Mosquito-Borne and Hemorrhagic Fever Viruses.Viruses · 2021Article
- Investigating Outbreaks of Salmonella Typhimurium Using Case-Control Studies, with a Reference to the One Health Approach.Methods in molecular biology (Clifton, N.J.) · 2021Article
- A palindromic RNA sequence as a common breakpoint contributor to copy-choice recombination in SARS-COV-2.Archives of virology · 2020Article
- Article
- Delayed recognition of Ebola virus disease is associated with longer and larger outbreaks.Emerging microbes & infections · 2020Article
- New methodologies for the estimation of population vulnerability to diseases: a case study of Lassa fever and Ebola in Nigeria and Sierra Leone.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Article
- Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.Journal of virology · 2019Article
- Article
- A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges.PloS one · 2019Article
- Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.Nature communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
85 authors at 17 institutions in 5 countries.
Augustine GobaViral Hemorrhagic Fever Program, Kenema Government Hospital.
S Humarr KhanViral Hemorrhagic Fever Program, Kenema Government Hospital.
Mbalu FonnieViral Hemorrhagic Fever Program, Kenema Government Hospital.
Mohamed FullahViral Hemorrhagic Fever Program, Kenema Government Hospital.
Alex MoigboiViral Hemorrhagic Fever Program, Kenema Government Hospital.
Alice KovomaViral Hemorrhagic Fever Program, Kenema Government Hospital.
Vandi SinnahViral Hemorrhagic Fever Program, Kenema Government Hospital.
Nancy YokoViral Hemorrhagic Fever Program, Kenema Government Hospital.
Hawa RogersViral Hemorrhagic Fever Program, Kenema Government Hospital.
Siddiki SafaiViral Hemorrhagic Fever Program, Kenema Government Hospital.
Mambu MomohViral Hemorrhagic Fever Program, Kenema Government Hospital.
Veronica KoromaViral Hemorrhagic Fever Program, Kenema Government Hospital.
Fatima K KamaraViral Hemorrhagic Fever Program, Kenema Government Hospital.
Edwin KonowuViral Hemorrhagic Fever Program, Kenema Government Hospital.
Mohamed YillahViral Hemorrhagic Fever Program, Kenema Government Hospital.
Issa FrenchViral Hemorrhagic Fever Program, Kenema Government Hospital.
Ibraham MustaphaViral Hemorrhagic Fever Program, Kenema Government Hospital.
Franklyn KannehViral Hemorrhagic Fever Program, Kenema Government Hospital.
Momoh FodayViral Hemorrhagic Fever Program, Kenema Government Hospital.
Helena McCarthyViral Hemorrhagic Fever Program, Kenema Government Hospital.
Tiangay KallonViral Hemorrhagic Fever Program, Kenema Government Hospital.
Mustupha KallonViral Hemorrhagic Fever Program, Kenema Government Hospital.
Jenneh NaiebuViral Hemorrhagic Fever Program, Kenema Government Hospital.
Josephine SelluViral Hemorrhagic Fever Program, Kenema Government Hospital.
Abdul A JallohViral Hemorrhagic Fever Program, Kenema Government Hospital.
Michael GbakieViral Hemorrhagic Fever Program, Kenema Government Hospital.
Lansana KannehViral Hemorrhagic Fever Program, Kenema Government Hospital.
James L B MassalyMinistry of Health and Sanitation.
David KargboMinistry of Health and Sanitation.
Brima KargboMinistry of Health and Sanitation.
Mohamed VandiMinistry of Health and Sanitation.
Momoh GbetuwaMinistry of Health and Sanitation.
Sahr M GevaoUniversity of Sierra Leone.
John D SandiViral Hemorrhagic Fever Program, Kenema Government Hospital.
Simbirie C JallohViral Hemorrhagic Fever Program, Kenema Government Hospital.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital Ministry of Health and Sanitation.
Sylvia O BlydenMinistry of Social Welfare, Gender, and Children's Affairs.
Ian CrozierWorld Health Organization Sierra Leone Ebola Response Team, Freetown, Sierra Leone Infectious Diseases Institute, Mulago Hospital Complex, Kampala, Uganda.
John S SchieffelinSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Susan L McLellanSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine Department of Tropical Medicine.
Shevin T JacobDivision of Allergy and Infectious Diseases, University of Washington, Seattle.
Matt L BoisenCorgenix, Broomfield, Colorado Zalgen Labs, Germantown, Maryland.
Jessica N HartnettDepartment of Microbiology and Immunology.
Robert W CrossDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston.
Luis M BrancoZalgen Labs, Germantown, Maryland.
Kristian G AndersenScripps Translational Science Institute.
Nathan L YozwiakBroad Institute of MIT and Harvard.
Stephen K GireNextGen Jane, San Francisco, California.
Ridhi TariyalNextGen Jane, San Francisco, California.
Daniel J ParkBroad Institute of MIT and Harvard.
Allyson M HaislipDepartment of Microbiology and Immunology.
Christopher M BishopDepartment of Microbiology and Immunology.
Lilia I MelnikDepartment of Microbiology and Immunology.
William R GallaherDepartment of Microbiology, Immunology, and Parasitology, LSU Health Mockingbird Nature Research Group, Pearl River, Louisiana.
William C WimleyDepartment of Biochemistry, Tulane University.
Jing HeDepartment of Biochemistry, Tulane University.
Jeffrey G ShafferDepartment of Biostatistics and Bioinformatics, Tulane School of Public Health and Tropical Medicine.
Brian M SullivanDepartment of Immunology and Microbial Science.
Sonia GrilloNaval Engineering Facilities Command, Naples, Italy.
Scott OmanSouth Coast Solar.
Courtney E GarrySection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine Autoimmune Technologies, New Orleans.
Donna R EdwardsMount Sinai School of Medicine.
Stephanie J McCormickAutoimmune Technologies, New Orleans.
Deborah H ElliottSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Julie A RouelleSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Chandrika B KannadkaSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Ashley A ReynaSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Benjamin T BradleySection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Haini YuSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Rachael E YenniDepartment of Microbiology and Immunology.
Kathryn M HastieDepartment of Immunology and Microbial Science.
Joan B GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston.
Peter C KulakoskyAutoimmune Technologies, New Orleans.
Russell B WilsonAutoimmune Technologies, New Orleans.
Michael B A OldstoneDepartment of Immunology and Microbial Science.
Kelly R PittsCorgenix, Broomfield, Colorado.
Lee A HendersonVybion, Ithaca, New York, New York.
James E RobinsonSection of Infectious Disease, Department of Pediatrics Section of Infectious Disease, Department of Internal Medicine, School of Medicine.
Thomas W GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston.
Erica Ollmann SaphireDepartment of Immunology and Microbial Science The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla.
Christian T HappiRedeemer's University, Ede Irrua Specialist Teaching Hospital, Nigeria.
Danny A AsogunIrrua Specialist Teaching Hospital, Nigeria.
Pardis C SabetiBroad Institute of MIT and Harvard Department of Organismic and Evolutionary Biology, Center for Systems Biology, Harvard University, Cambridge, Massachusetts.
Robert F GarryDepartment of Microbiology and Immunology Zalgen Labs, Germantown, Maryland.
Viral Hemorrhagic Fever Consortium
Autoimmune Technologies (United States) · USThe University of Texas Medical Branch at Galveston · USTulane University · USZalgen (United States) · USBroad Institute · USIrrua Specialist Teaching Hospital · NGNextGen Aeronautics (United States) · USScripps Research Institute · USCenter for Systems Biology · USCorgenix (United States) · USIcahn School of Medicine at Mount Sinai · USLouisiana State University Health Sciences Center New Orleans · USMinistry of Health and Social Welfare · TZMulago Hospital · UGUniversity of Sierra Leone · SLUniversity of Washington · USVybion (United States) · US
Funding
Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI CUOMO, CHRISTINA A · 2014 to 2024
$66.5MMechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6MTulane Building Interdisciplinary Research Careers in Women's Health (BIRCWH)K12HD043451 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KROUSEL-WOOD, MARIE · 2002 to 2023
$9.9MPreclinical development of recombinant antigen diagnostics for Lassa feverU01AI082119 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2009 to 2013
$6.7MMentoring Translational Researchers in LouisianaP20GM103501 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2012 to 2014
$6.3MAntibody immunotherapeutics for biodefense against Lassa virusR01AI104621 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2013 to 2017
$5.8MRecombinant antigen assays for Lassa and other arenaviruUC1AI067188 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2005 to 2005
$3.9MProject 2. Expansion of Clinical Research Capacity at Kenema Government HospitalU19AI115589 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2015 to 2019
$3.6MEBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSISR01AI067927 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2006 to 2013
$3.6MImmunotherapeutics vs Ebola Sudan: Development, Structural & Functional AnalysisU01AI070530 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2006 to 2010
$3.5MRecombinant antigen diagnostics for filovirusesR44AI088843 · NIAID · ZALGEN LABS, LLC · PI BOISEN, MATTHEW L · 2014 to 2016
$3.0MSTRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITER01AI081982 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2010 to 2014
$2.8MNHGRI NIH HHS U01 HG007480NIAID NIH HHS HHSN272201000022CNIAID NIH HHS HHSN272201400048CNIAID NIH HHS R01 AI067927NIAID NIH HHS R01 AI081982NIAID NIH HHS R01 AI104621NIAID NIH HHS R13 AI104216NIAID NIH HHS R43 AI088843NIAID NIH HHS R44 AI088843NIAID NIH HHS R44 AI115754NIAID NIH HHS U01 AI070530NIAID NIH HHS U01 AI082119NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI110818NIAID NIH HHS U19 AI115589NIAID NIH HHS UC1 AI067188NICHD NIH HHS K12 HD043451NIGMS NIH HHS P20 GM103501World Health Organization 001
Abstract
backgroundKenema Government Hospital (KGH) has developed an advanced clinical and laboratory research capacity to manage the threat of Lassa fever, a viral hemorrhagic fever (VHF). The 2013-2016 Ebola virus (EBOV) disease (EVD) outbreak is the first to have occurred in an area close to a facility with established clinical and laboratory capacity for study of VHFs.
methodsBecause of its proximity to the epicenter of the EVD outbreak, which began in Guinea in March 2014, the KGH Lassa fever Team mobilized to establish EBOV surveillance and diagnostic capabilities.
resultsAugustine Goba, director of the KGH Lassa laboratory, diagnosed the first documented case of EVD in Sierra Leone, on 25 May 2014. Thereafter, KGH received and cared for numbers of patients with EVD that quickly overwhelmed the capacity for safe management. Numerous healthcare workers contracted and lost their lives to EVD. The vast majority of subsequent EVD cases in West Africa can be traced back to a single transmission chain that includes this first diagnosed case.
conclusionsResponding to the challenges of confronting 2 hemorrhagic fever viruses will require continued investments in the development of countermeasures (vaccines, therapeutic agents, and diagnostic assays), infrastructure, and human resources.
Indexed as
Disease OutbreaksAdolescentAdultAfrica, WesternChildChild, PreschoolEbolavirusEpidemiological MonitoringFemaleGenome, ViralGenomicsGuineaHemorrhagic Fever, EbolaHumansLassa FeverLassa virusEbola virusepidemiologygenomic sequencingLassa virusresearch capacity buildingviral hemorrhagic fever diagnosticsWest African Ebola outbreak 2013–16
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.